Wei Ying Jen, MA (Oxon), BM BCh, M Med (Internal Medicine), MRCP (UK), FRCPath (UK, Haematology)
Department of Leukemia, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2019 | Royal College of Pathologists, GB, Haematolgy, Fellowship of the Royal College of Pathologists |
| 2015 | National University of Singapore, Singapore, SG, Internal Medicine, Master of Medicine |
| 2015 | University of Oxford, Oxford, Oxfordshire, GB, Master of Arts |
| 2015 | Royal College of Physicians, GB, Membership of the Royal College of Physicians |
| 2012 | University of Oxford, Oxford, Oxfordshire, GB, Bachelor of Medicine and Bachelor of Surgery |
| 2009 | University of Oxford, Oxford, Oxfordshire, GB, Medical Sciences, Bachelor of Arts |
Postgraduate Training
| 2023-2024 | Fellow, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2016-2019 | Senior Resident, Haematology, National University Cancer Institute, Singapore, Singapore, Singapore |
| 2013-2016 | Resident, Internal Medicine, National University Hospital, Singapore, Singapore |
| 2013-2013 | House Officer, General Medicine, National University Hospital, Singapore, Singapore |
| 2013-2013 | House Officer, KK Women's & Children's Hospital, Singapore, Singapore |
| 2012-2013 | House Officer, Singapore General Hospital, Singapore, Singapore |
Licenses & Certifications
| 2025 | Texas Medical Board Physician License |
| 2025 | Texas Medical Board Faculty Temporary License |
| 2024 | Drug Enforcement Agency Controlled Substance Registration Certificate |
| 2024 | Texas Medical Board Faculty Temporary License |
| 2023 | Texas Physician-In-Training Permit |
| 2022 | Education Commission of Foreign Medical Graduates |
| 2019 | Certificate of Specialist Accreditation |
| 2016 | Singapore Medical Council Certificate of Medical Registration |
| 2016 | General Medical Council (UK) Registration |
Experience & Service
Faculty Academic Appointments
Adjunct Assistant Professor, Department of Medicine, National University of Singapore Yong Loo Lin School of Medicine, Singapore, Singapore, 2023 - 2024
Senior Lecturer, Department of Medicine, National University of Singapore Yong Loo Lin School of Medicine, Singapore, Singapore, 2019 - 2023
Clinical Lecturer, Department of Medicine, National University of Singapore Yong Loo Lin School of Medicine, Singapore, Singapore, 2017 - 2019
Administrative Appointments/Responsibilities
Undergraduate Division Director, Department of Medicine, National University of Singapore Yong Loo Lin School of Medicine, Singapore, Singapore, 2022 - 2024
System Block Lead, Department of Medicine, National University of Singapore Yong Loo Lin School of Medicine, Singapore, Singapore, 2021 - 2023
Intramural Institutional Committee Activities
Member, Telemedicine Committee, National University Health System, 2020 - 2024
Member, NUHS App Workgroup, National University Health System, 2020 - 2024
Member, NCIS Right Siting Workgroup, National University Cancer Institute, Singapore, 2019 - 2024
Member, NCIS Annual Research Meeting Scientific Committee, National University Cancer Institute, Singapore, 2018 - 2020
Member, Resident's Research Committee, National University Health System, 2018 - 2019
Member, Residents' Welfare Committee, National University Health System, 2015 - 2016
Extramural Institutional Committee Activities
Member, Cogent Systemic Mastocytosis Scientific Advisory Board, MD Education, 2026 - Present
Member, MD Anderson Institutional Review Board, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, Academic Review Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Key Opinion Leader, Singapore Translational Cancer Consortium, Singapore Translational Cancer Consortium, 2022 - Present
Member, Asia-Pacific Leukaemia Consortium, Asia-Pacific Leukaemia Consortium, 2022 - Present
Chairperson, Institutional Review Board, Nanyang Girls' High School, 2017 - 2019
Honors & Awards
| 2024 | EHA Educational Travel Grant, European Hematology Association |
| 2024 | Conquer Cancer – Eisai Inc. Endowed Merit Award, American Society of Clinical Oncology |
| 2023 | NCIS SHINE Incredible Care Award, Nominated by peers, allied health and supervisors to recognise staff who have contributed significantly to the institution and positively influenced their teams |
| 2022 | The Public Administration Medal (Bronze) (COVID-19), Prime Minister's Office, Singapore |
| 2022 | NCIS SHINE Incredible People Award, National University Cancer Institute, Singapore |
| 2020 | Quality Improvement Project Merit Award, National University Hospital |
| 2020 | Best Trainee Award, Chapter of Haematologists, College of Physicians, Academy of Medicine, Singapore |
| 2017 | Best Senior Resident Tutor Award, University Medicine Cluster, National University Hospital |
| 2016 | Junior Doctor Teaching Award, National University of Singapore Yong Loo Lin School of Medicine |
| 2014 | Best Poster Award, World Congress of Internal Medicine |
| 2012 | St Catherine's College Book Prize, St Catherine's College, University of Oxford |
| 2011 | Wellcome Trust Student Elective Prize, Wellcome Trust |
| 2010 | Glaxo Scholarship, St Catherine's College, University of Oxford |
| 2010 | Light Senior Scholarship, St Catherine's College, University of Oxford |
| 2009 | St Catherine's College Book Prize, St Catherine's College, University of Oxford |
| 2009 | Gibbs Prize, Pre-Clinical Faculty Office, University of Oxford |
| 2008 | College Exhibition, St Catherine's College, University of Oxford |
Professional Memberships
Selected Presentations & Talks
National Presentations
- 2026. Outcomes and natural history of telomere biology disorders in patients without a concurrent hematological disorder. Conference. Genetic Basis of Blood Cancers and Bone Marrow Failure. Niagra Falls, New York, US.
- 2025. Phase II Study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML. Conference. American Society of Hematology. Orlando, Florida, US.
International Presentations
- 2026. KMT2A-PTD in AML. Invited. 5th Translational Summit on Hematologic Malignancies, BM.
- 2026. Tagraxofusp, a first-in-class CD123-targeted agent, five years after its approval for BPDCN. Invited. 5th Translational Summit on Hematologic Malignancies, BM.
- 2026. Outcome of second-line therapy in adult b-cell Philadelphia chromosome positive acute lymphoblastic leukemia. Conference. European Hematology Association Annual Congress. Stockholm, SE.
- 2026. Outcome of second-line therapy in adult b-cell Philadelphia chromosome positive acute lymphoblastic leukemia. Conference. European Hematology Association Annual Congress. Stockholm, SE.
- 2025. Risk stratification of newly diagnosed acute myeloid leukemia treated with venetoclax in combination with intensive chemotherapy. Panelist.
- 2025. Outcomes of the acute myeloid leukemia-defining MECOM rearrangement differ based on blast count at diagnosis. Conference. European Hematology Association Annual Congress. Milan, IT.
- 2025. Risk stratification of newly diagnosed acute myeloid leukemia treated with venetoclax in combination with intensive chemotherapy. Conference. European Hematology Association Annual Congress. Milan, IT.
- 2024. FLAG-IDA + venetoclax (VEN) in newly diagnosed (ND) or relapsed / refractory (RR) AML. Conference. European Hematology Association Annual Congress. Madrid, ES.
Patient Reviews
CV information above last modified September 03, 2026